NEW YORK, June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts ...
Inflammatory bowel disease (IBD) patients face significant health care access barriers, leading to medication rationing and adverse health outcomes. Key issues include appointment availability and ...
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback